As a reminder, Brazil has the largest prevalence of hATTR amyloidosis polyneuropathy patients worldwide. Building on our core capabilities in LatAm, we anticipate a Waylivra filing with ANVISA in the second half of this year and continue to identify new FCS patients for Waylivra therapy. Turning to AADC deficiency. Prelaunch activities continue to progress.